NEW YORK, Jan. 28, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Talis Biomedical Corporation (NASDAQ: TLIS) and Oak Street Health, Inc. (NYSE: OSH). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
Talis Biomedical Corporation (NASDAQ: TLIS)
Class Period: February 12, 2021 IPO
Lead Plaintiff Deadline: March 8, 2022
The complaint filed in this class action alleges that the Registration Statement was false and misleading and omitted to state material adverse facts. Specifically, Defendants failed to disclose to investors: (1) that the comparator assay in the primary study lacked sufficient sensitivity to support Talis’s EUA application for Talis One COVID-19 test; (2) that, as a result, Talis was reasonably likely to experience delays in obtaining regulatory approval for the Talis One COVID-19 test; (3) that, as a result, the Company’s commercialization timeline would be significantly delayed; and (4) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.
By the commencement of this action, Talis stock has traded as low as $3.81 per share, a more than 76% decline from the $16 per...
Did Trump announce that USS Abraham Lincoln personnel must sign nondisclosure agreements before leaving the ship? Anti-Vaxxers Blame Vaccines for a Supposed Spike in Pet Cancers By Andie Slomka Wha...